U.S. Markets closed

4 Biotechs on Verge of Big Breakouts

Michael Kramer

The large-cap biotech stocks have been left in the dust this year with the iShares Nasdaq Biotechnology ETF ( IBB) rising by only 8.7%. This, by most standards, is a healthy gain compared to the S&P 500 rise of only 3%. Signs are emerging that the larger-cap biotechs are poised to break out in the near term, and that could send stocks like Celgene Corp. ( CELG), Gilead Sciences, Inc. ( GILD), Amgen Inc. ( AMGN) and Alexion Pharmaceuticals, Inc. ( ALXN) much higher.